An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304.
Phase of Trial: Phase III
Latest Information Update: 24 Jan 2018
At a glance
- Drugs Everolimus (Primary)
- Indications Seizures; Tuberous sclerosis
- Focus Adverse reactions; Registrational
- Sponsors Novartis Pharmaceuticals
- 30 Jun 2017 Status changed from not yet recruiting to recruiting.
- 07 May 2017 Planned End Date changed from 27 Apr 2027 to 5 Jan 2028.
- 07 May 2017 Planned primary completion date changed from 27 Apr 2027 to 2 Apr 2027.